Jundishapur Journal of Microbiology

Published by: Kowsar

In Silico Analysis and Expression of Influenza Virus 3M2e-HA2 Chimer Protein Fused to C-Terminal Domain of Leishmania major HSP70

Elahe Nazeri 1 , 2 , Behrokh Farahmand 1 , * , Fatemeh Fotouhi 1 , Mehrdad Hashemi 2 , Najme Taheri 1 , Hadis Shokohi 1 and Shekoofe Hatami 1
Authors Information
1 Department of Influenza and Other Respiratory Viruses, Pasteur Institute of Iran, Tehran, Iran
2 Department of New Sciences, Tehran Medical Sciences Branch, Islamic Azad University, Tehran, Iran
Article information
  • Jundishapur Journal of Microbiology: August 2018, 11 (8); e13777
  • Published Online: July 18, 2018
  • Article Type: Research Article
  • Received: May 21, 2017
  • Revised: March 17, 2018
  • Accepted: April 29, 2018
  • DOI: 10.5812/jjm.13777

To Cite: Nazeri E, Farahmand B, Fotouhi F, Hashemi M, Taheri N, et al. In Silico Analysis and Expression of Influenza Virus 3M2e-HA2 Chimer Protein Fused to C-Terminal Domain of Leishmania major HSP70, Jundishapur J Microbiol. 2018 ; 11(8):e13777. doi: 10.5812/jjm.13777.

Copyright © 2018, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Berlanda Scorza F, Tsvetnitsky V, Donnelly JJ. Universal influenza vaccines: Shifting to better vaccines. Vaccine. 2016;34(26):2926-33. doi: 10.1016/j.vaccine.2016.03.085. [PubMed: 27038130]. [PubMed Central: PMC4899887].
  • 2. Li J, Arevalo MT, Chen Y, Posadas O, Smith JA, Zeng M. Intranasal immunization with influenza antigens conjugated with cholera toxin subunit B stimulates broad spectrum immunity against influenza viruses. Hum Vaccin Immunother. 2014;10(5):1211-20. doi: 10.4161/hv.28407. [PubMed: 24632749]. [PubMed Central: PMC4896531].
  • 3. de Vries RD, Altenburg AF, Rimmelzwaan GF. Universal influenza vaccines: a realistic option? Clin Microbiol Infect. 2016;22 Suppl 5:S120-4. doi: 10.1016/j.cmi.2015.12.005. [PubMed: 27130671].
  • 4. Tompkins SM, Zhao ZS, Lo CY, Misplon JA, Liu T, Ye Z, et al. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis. 2007;13(3):426-35. doi: 10.3201/eid1303.061125. [PubMed: 17552096]. [PubMed Central: PMC2725899].
  • 5. Jang YH, Seong BL. Options and obstacles for designing a universal influenza vaccine. Viruses. 2014;6(8):3159-80. doi: 10.3390/v6083159. [PubMed: 25196381]. [PubMed Central: PMC4147691].
  • 6. Kesik-Brodacka M, Plucienniczak G. A universal flu vaccine. Acta Biochim Pol. 2014;61(3):523-30. [PubMed: 25203218].
  • 7. Liu W, Zou P, Ding J, Lu Y, Chen YH. Sequence comparison between the extracellular domain of M2 protein human and avian influenza A virus provides new information for bivalent influenza vaccine design. Microbes Infect. 2005;7(2):171-7. doi: 10.1016/j.micinf.2004.10.006. [PubMed: 15777646].
  • 8. Rappazzo CG, Watkins HC, Guarino CM, Chau A, Lopez JL, DeLisa MP, et al. Recombinant M2e outer membrane vesicle vaccines protect against lethal influenza A challenge in BALB/c mice. Vaccine. 2016;34(10):1252-8. doi: 10.1016/j.vaccine.2016.01.028. [PubMed: 26827663].
  • 9. Sui J, Hwang WC, Perez S, Wei G, Aird D, Chen LM, et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol. 2009;16(3):265-73. doi: 10.1038/nsmb.1566. [PubMed: 19234466]. [PubMed Central: PMC2692245].
  • 10. Alvarado-Facundo E, Gao Y, Ribas-Aparicio RM, Jimenez-Alberto A, Weiss CD, Wang W. Influenza virus M2 protein ion channel activity helps to maintain pandemic 2009 H1N1 virus hemagglutinin fusion competence during transport to the cell surface. J Virol. 2015;89(4):1975-85. doi: 10.1128/JVI.03253-14. [PubMed: 25473053]. [PubMed Central: PMC4338904].
  • 11. Ebrahimi SM, Dabaghian M, Tebianian M, Jazi MH. In contrast to conventional inactivated influenza vaccines, 4xM2e.HSP70c fusion protein fully protected mice against lethal dose of H1, H3 and H9 influenza A isolates circulating in Iran. Virology. 2012;430(1):63-72. doi: 10.1016/j.virol.2012.04.015. [PubMed: 22595444].
  • 12. Ebrahimi SM, Tebianian M. Heterologous expression, purification and characterization of the influenza A virus M2e gene fused to Mycobacterium tuberculosis HSP70(359-610) in prokaryotic system as a fusion protein. Mol Biol Rep. 2010;37(6):2877-83. doi: 10.1007/s11033-009-9846-2. [PubMed: 19813102].
  • 13. Jalili N, Taheri N, Tavakoli R, Fotoohi F, Akbari A, Farahmand B. [Expression and Purification of a Recombinant Chimeric Protein (3M2e-HA2) Composed of Influenza Virus Hemaglutinin and Matrix Protein Conserved Domain for Universal Subunit Vaccine Development]. J Mazandaran U Med Sci. 2016;26(137):12-22. Persian.
  • 14. Wilkins MR, Gasteiger E, Bairoch A, Sanchez JC, Williams KL, Appel RD, et al. Protein identification and analysis tools in the ExPASy server. Methods Mol Biol. 1999;112:531-52. [PubMed: 10027275].
  • 15. Geourjon C, Deleage G. SOPMA: significant improvements in protein secondary structure prediction by consensus prediction from multiple alignments. Comput Appl Biosci. 1995;11(6):681-4. [PubMed: 8808585].
  • 16. Zhang Y. I-TASSER server for protein 3D structure prediction. BMC Bioinformatics. 2008;9:40. doi: 10.1186/1471-2105-9-40. [PubMed: 18215316]. [PubMed Central: PMC2245901].
  • 17. Lovell SC, Davis IW, Arendall WB, Bakker PI, Word JM, Prisant MG, et al. Structure validation by Calpha geometry: phi,psi and Cbeta deviation. Proteins. 2003;50(3):437-50. doi: 10.1002/prot.10286. [PubMed: 12557186].
  • 18. Wiederstein M, Sippl MJ. ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Res. 2007;35(Web Server issue):W407-10. doi: 10.1093/nar/gkm290. [PubMed: 17517781]. [PubMed Central: PMC1933241].
  • 19. Saha S, Raghava GP. Prediction of continuous B-cell epitopes in an antigen using recurrent neural network. Proteins. 2006;65(1):40-8. doi: 10.1002/prot.21078. [PubMed: 16894596].
  • 20. Ponomarenko J, Bui HH, Li W, Fusseder N, Bourne PE, Sette A, et al. ElliPro: a new structure-based tool for the prediction of antibody epitopes. BMC Bioinformatics. 2008;9:514. doi: 10.1186/1471-2105-9-514. [PubMed: 19055730]. [PubMed Central: PMC2607291].
  • 21. Bhasin M, Raghava GP. Prediction of CTL epitopes using QM, SVM and ANN techniques. Vaccine. 2004;22(23-24):3195-204. doi: 10.1016/j.vaccine.2004.02.005. [PubMed: 15297074].
  • 22. Ebrahimi SM, Tebianian M. Role of mycobacterial heat shock protein 70 (mHSP70) as genetic vaccine adjuvants. World Appl Sci J. 2011;14(10):1569-75.
  • 23. Li X, Yang X, Li L, Liu H, Liu J. A truncated C-terminal fragment of Mycobacterium tuberculosis HSP70 gene enhanced potency of HBV DNA vaccine. Vaccine. 2006;24(16):3321-31. doi: 10.1016/j.vaccine.2006.01.012. [PubMed: 16472546].
  • 24. Rico AI, Angel SO, Alonso C, Requena JM. Immunostimulatory properties of the Leishmania infantum heat shock proteins HSP70 and HSP83. Mol Immunol. 1999;36(17):1131-9. [PubMed: 10698315].
  • 25. Udono H, Yamano T, Kawabata Y, Ueda M, Yui K. Generation of cytotoxic T lymphocytes by MHC class I ligands fused to heat shock cognate protein 70. Int Immunol. 2001;13(10):1233-42. [PubMed: 11581168].
  • 26. Rafati S, Gholami E, Hassani N, Ghaemimanesh F, Taslimi Y, Taheri T, et al. Leishmania major heat shock protein 70 (HSP70) is not protective in murine models of cutaneous leishmaniasis and stimulates strong humoral responses in cutaneous and visceral leishmaniasis patients. Vaccine. 2007;25(21):4159-69. doi: 10.1016/j.vaccine.2007.03.006. [PubMed: 17395340].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments